UTMB-Novartis Alliance for Pandemic Preparedness

UTMB-诺华流行病防范联盟

基本信息

批准号：
10845855
负责人：
Thierry Diagana
金额：
$ 1884.9万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10845855
关键词：
2019-nCoV Academia Air Antiviral Agents Biology COVID-19 COVID-19 assay COVID-19 pandemic Cells Cessation of life Clinical Collaborations Communicable Diseases Communication Complex Coronavirus Data Decision Making Dengue Development Diagnostic Drug Targeting Education Emerging Technologies Ensure Faculty Family Flavivirus Foundations Future Generations Goals Hendra Virus Henipavirus Home Human Humanities Industry Infection Institution Intellectual Property Investments Laboratories Learning Libraries Life Machine Learning Marketing Medical Medicine Membrane Proteins Mentors Middle East Respiratory Syndrome Coronavirus Nipah Virus Nongovernmental Organizations Nucleosides Nucleotides Oral Peptide Hydrolases Pharmaceutical Preparations Pharmacologic Substance Phase I Clinical Trials Phenotype Polymerase Population Density Postdoctoral Fellow Predisposition Private Sector Privatization Probability Process Productivity Protease Inhibitor Quantitative Structure-Activity Relationship RNA-Directed RNA Polymerase Rationalization Research Research Activity Research Project Grants Resistance SARS-CoV-2 inhibitor Seasons Serotyping Spanish flu Technology Texas Training Translational Research Travel United States National Institutes of Health Universities Vaccines Viral Virus biosafety level 4 facility clinical candidate clinical investigation combat drug candidate drug discovery economic cost inhibitor innovation mortality multidisciplinary new technology next generation novel pandemic disease pandemic potential pandemic preparedness prevent pandemics programs public health relevance public-private partnership recruit response role model screening student training success synergism translational impact viral pandemic virology

项目摘要

OVERALL – ABSTRACT Pandemic prevention and preparedness is a major scientific and societal priority that requires sustained and forward looking investments across governmental, non-governmental, academic and private sectors to develop an arsenal of countermeasures against the existential threat of viral pandemics. Combining world-leading BSL3/4 capabilities at University of Texas of Medical Branch (UTMB) and state-of-the art drug discovery technologies at Novartis, the UTMB Novartis Alliance for Pandemic Preparedness (UNAPP), is a unique and innovative partnership that brings together the multi-disciplinary expertise required to deliver high quality antiviral drug candidates. Enabled by world-leading virologists and seasoned drug hunters, UNAPP will aggressively prosecute a portfolio of 5 projects aiming to discover orally available, safe, and effective drugs against coronaviruses, flavivirus and henipavirus, three major classes of viruses with pandemic potential. The projects portfolio combines approaches targeting well validated drug targets, such as the RNA- dependent RNA polymerases and viral proteases, as well as phenotypic screening, which will allow for the discovery of clinical drug candidates and novel targets that will advance our fundamental understanding of the biology of those viruses. Four scientific Cores—Virology, High-Throughput Biology, Drug Discovery and Translational Research Cores—will provide technological and scientific expertise to support Project Teams and implement the scientific strategy toward novel antiviral drugs. The UNAPP will be governed by an Administrative Core which will be co-led by the PIs, Dr. Pei-Yong Shi and Dr. Thierry Diagana, who have a long track-record of successfully working together. Both PIs have led multiple productive collaborations focused on translational impact and combining public, private and non-governmental organizations. The Administrative Core will provide integrated decision making in scientific, operational, financial, intellectual property protection, and communication. In collaboration with all project and Core leaders, as well as with external input from a Scientific Advisory Board and NIH program officers, they will ensure that the projects portfolio leverages the full spectrum of technologies and capabilities residing in all four scientific Cores, capturing synergies across projects through cross-learning and efficient deployment of platforms relevant to multiple viruses. Because of the unique complementarity of the scientific Cores and the remarkable synergies of the project portfolio, we fully expect that the UNAPP will yield exceptional productivity and deliver all the proposed objectives: (1) Deliver 3 IND-ready candidates and 3 Development Candidates, (2) advance antiviral research, and (3) train next-generation drug hunters.

总体 – 摘要大流行病的预防和准备是一项重大的科学和社会优先事项，需要持续和政府、非政府、学术和私营部门的前瞻性投资，以发展结合世界领先的应对病毒流行病生存威胁的一系列对策。德克萨斯大学医学分校 (UTMB) 的 BSL3/4 能力和最先进的药物发现诺华 (UTMB) 诺华流行病防范联盟 (UNAPP) 的技术是一项独特的技术和创新的合作伙伴关系，汇集了提供高质量所需的多学科专业知识在世界领先的病毒学家和经验丰富的药物搜寻者的支持下，UNAPP 将开发抗病毒候选药物。积极开发 5 个项目组合，旨在发现口服、安全和有效的药物对抗冠状病毒、黄病毒和亨尼帕病毒这三大类大流行病毒该项目组合结合了针对经过充分验证的药物靶点的方法，例如 RNA- 依赖的RNA聚合酶和病毒蛋白酶，以及表型筛选，这将允许临床候选药物和新靶点的发现将增进我们对药物的基本理解这些病毒的生物学。四个科学核心——病毒学、高通量生物学、药物发现和转化研究核心——将提供技术和科学专业知识来支持项目团队和实施新型抗病毒药物的科学战略 UNAPP 将由行政部门管理。核心将由 PI 博士 Pei-Yong Shi 和 Thierry Diagana 博士共同领导，他们在两位 PI 领导了多次富有成效的合作，重点关注转化。行政核心将提供影响力并结合公共、私人和非政府组织。科学、运营、财务、知识产权保护等方面的综合决策与所有项目和核心领导者合作，以及科学界的外部投入。顾问委员会和 NIH 项目官员，他们将确保项目组合利用全方位属于所有四个科学核心的技术和能力，通过以下方式捕获项目之间的协同效应多种病毒相关平台的交叉学习和高效部署。科学核心的互补性和项目组合的显着协同效应，我们完全期望 UNAPP 将产生卓越的生产力并实现所有拟议目标：(1) 实现 3 IND 就绪候选人和 3 名发展候选人，(2) 推进抗病毒研究，以及 (3) 培训下一代毒品猎人

项目成果

期刊论文数量（2）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions.

SARS-CoV-2 的 NSP3 蛋白结合脆弱的 X 智力迟钝蛋白，破坏 UBAP2L 相互作用。

DOI：
发表时间：
2024-02
期刊：
影响因子：
7.7
作者：
Garvanska, Dimitriya H;Alvarado, R Elias;Mundt, Filip Oskar;Lindqvist, Richard;Duel, Josephine Kerzel;Coscia, Fabian;Nilsson, Emma;Lokugamage, Kumari;Johnson, Bryan A;Plante, Jessica A;Morris, Dorothea R;Vu, Michelle N;Estes, Leah K;McLeland
通讯作者：
McLeland

Reverse genetic systems of SARS-CoV-2 for antiviral research.

用于抗病毒研究的 SARS-CoV-2 反向遗传系统。